CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tamir Biotechnology Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tamir Biotechnology Inc
12625 High Bluff Dr.
Suite 113
San Diego, CA  92130  United States

This company was Merged or Acquired on 4/27/2020.
On 6/20/2013, the U.S. Securities and Exchange Commission revoked the registration of each class of registered securities of Tamir Biotechnology Inc for failure to make required periodic filings with the Commission.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Tamir Biotechnology, Inc. is a United States-based company that develops biopharmaceutical products. The Company offers biopharmaceutical product candidate that works in a manner similar to ribonucleic acid interference (RNAi) through late-stage clinical trials. Its product candidate, ONCONASE, is a therapeutic based on its ribonuclease (RNase) technology. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action. Its drug discovery program is also the basis for the development of recombinant designed RNases for chemical conjugation and fusion (gene and protein) products with various targeting moieties, such as monoclonal antibodies, growth factors, and cytokines. This program also provides for joint design and development of new products with outside partners seeking line-extensions and/or improvements of the therapeutic effectiveness of their existing products.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
1/31/20117/31/2010YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board DavidSidransky 52 1/17/2008 5/1/2004
President, Director Jamie M.Sulley 2/5/2013 2/5/2013
Chief Financial Officer, Principal Financial Officer Joanne M.Barsa 2/5/2013 2/5/2013
4 additional Officers and Directors records available in full report.

General Information
Number of Employees: 3 (As of 1/31/2011)
Outstanding Shares: 217,364,331 (As of 4/25/2013)
Shareholders: 968
Stock Exchange: OTC
Federal Tax Id: 222369085
Email Address: InvestorInfo@alfacell.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023